RxDoctor Payments DataLook up a doctor →

Timothy Wierzbicki, MD

Neurology · Port Orange, FLNPI 1134145741

Payments from drug & device makers

$1,668,652in general payments, 2019–2025

Across 223 payments — averaging $7482.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$568K
  • Vertex$413K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$176K
  • UCB SA$149K
  • Sage Therapeutics, LLC$120K
  • Eli Lilly$85K
  • plus $157K from 35 others
$15,768in research payments, 2019–2025

Across 2 payments — averaging $7884.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$16K

What the payments were for

  • Speaking & faculty fees$181%
  • Food & beverage$1,46190%
  • Education$1509%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,668,652 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$1,221,616
Medicare patients
693
Services billed
10,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5071$994,734
IngrezzaValbenazine Tosylate11$86,473
Emgality PenGalcanezumab-Gnlm75$64,052
Nurtec OdtRimegepant Sulfate21$39,732
Aimovig AutoinjectorErenumab-Aooe33$27,878
XareltoRivaroxaban30$24,242
Carbidopa-LevodopaCarbidopa/Levodopa398$15,319
Divalproex Sodium ErDivalproex Sodium508$13,668
Rivastigmine41$10,834
Donepezil Hcl1,018$10,405
Pyridostigmine Bromide87$9,747
Memantine Hcl277$9,334
Dalfampridine ErDalfampridine13$9,000
RivastigmineRivastigmine Tartrate127$7,474
Entacapone32$5,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$36$994,73471 claims
Neurocrine Biosciences, Inc.Ingrezza$16$86,47311 claims
PfizerNurtec Odt$39$39,73221 claims
Johnson & JohnsonXarelto$14$24,24230 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$36$11,184111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.

Other neurology in Port Orange

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →